Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17955607 | 0.87 | USP2 (0.52) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL12014360 | 0.82 | USP2 (0.47) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL11186 | 0.79 | USP2 (0.78) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL4384137 | 0.79 | USP2 (0.78) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL4388837 | 0.79 | USP2 (0.78) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL22470454 | 0.78 | USP2 (0.56) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL3101596 | 0.77 | USP2 (0.56) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL4501023 | 0.77 | USP2 (0.56) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL6696422 | 0.77 | USP2 (0.56) | USP2ALDH1A1ANPEPKDM4EMEN1 | |
| SCHEMBL6696413 | 0.77 | USP2 (0.56) | USP2ALDH1A1ANPEPKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017023445-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170027898-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170027898-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2017-02-02 | — | — | US | disclosed |
| US-9403784-B1 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403784-B1 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027898-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | USP2 1517/4885ALDH1A1 1949/4885ANPEP 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.